Clinical trial
Safety Study of Syntropin (Human Growth Hormone) for the Treatment of Growth…
NCT00489294 · Phage Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00489294 |
|---|---|
| Title | Safety Study of Syntropin (Human Growth Hormone) for the Treatment of Growth Hormone Deficiency |
| Official title | An Open-Label Study of the Pharmacokinetics and Pharmacodynamics of Syntropin (a Human Growth Hormone) in Growth Hormone-Suppressed Healthy Volunteers |
| Lead sponsor | Phage Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Growth Hormone Deficiency |
| Intervention type | Drug |
| Interventions | Syntropin |
| Enrollment | 20 |
| Start date | Aug 1, 2004 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Jun 21, 2007 |
| Last update posted | Mar 12, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: